Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis

Next Previous
Search
Trial Profile

A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolebrutinib (Primary) ; Gadolinium-containing contrast agents
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sanofi; Sanofi Genzyme

    • Most Recent Events

    • 27 Apr 2023 Results assessing the utility of actigraphy in measuring gait changes in participants with progressive multiple sclerosis, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 27 Apr 2023 Results assessing potential rebound disease recrudescence in participants with relapsing multiple sclerosis (MS) after tolebrutinib, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 01 Sep 2021 Results published in the Lancet Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top